LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Home・Aandelen Lijst・Kura Oncology Inc

Kura Oncology Inc

Gesloten

SectorGezondheidszorg

9.74 2.96

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

9.43

Max

9.98

Belangrijke statistieken
By Trading Economics
Inkomsten	-6.9M -81M
Verkoop	-3.4M 17M
Winstmarge	-467.23
Werknemers	260
EBITDA	-12M -86M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+190.6% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	89M 844M
Vorige openingsprijs	6.78
Vorige sluitingsprijs	9.74

Nieuwssentiment

By Acuity

19%

81%

41 / 346 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

5.575 / 6.6 Steun & Weerstand

Kura Oncology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 mei 2026, 22:54 UTC

Winsten

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 mei 2026, 23:51 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

13 mei 2026, 23:51 UTC

Marktinformatie

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 mei 2026, 23:45 UTC

Marktinformatie

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 mei 2026, 23:45 UTC

Marktinformatie

Global Equities Roundup: Market Talk

13 mei 2026, 23:17 UTC

Winsten

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 mei 2026, 23:16 UTC

Winsten

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 mei 2026, 23:15 UTC

Winsten

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 mei 2026, 23:14 UTC

Winsten

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 mei 2026, 23:02 UTC

Marktinformatie

Winsten

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 mei 2026, 22:59 UTC

Marktinformatie

Winsten

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 mei 2026, 22:24 UTC

Winsten

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 mei 2026, 22:23 UTC

Winsten

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 mei 2026, 22:23 UTC

Winsten

Xero FY International Revenue Growth 47%>XRO.AU

13 mei 2026, 22:22 UTC

Winsten

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 mei 2026, 22:19 UTC

Winsten

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 mei 2026, 22:19 UTC

Winsten

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 mei 2026, 22:18 UTC

Winsten

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 mei 2026, 22:16 UTC

Winsten

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 mei 2026, 22:15 UTC

Winsten

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 mei 2026, 22:15 UTC

Winsten

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 mei 2026, 22:13 UTC

Winsten

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 mei 2026, 22:12 UTC

Winsten

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 mei 2026, 22:11 UTC

Winsten

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 mei 2026, 22:11 UTC

Winsten

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 mei 2026, 22:10 UTC

Winsten

Xero Did Not Declare a Dividend>XRO.AU

13 mei 2026, 22:10 UTC

Winsten

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 mei 2026, 22:09 UTC

Winsten

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 mei 2026, 22:00 UTC

Winsten

Cisco to Shed Jobs for All-In AI Push -- Update

13 mei 2026, 21:11 UTC

Winsten

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Peer Vergelijking

Prijswijziging

Kura Oncology Inc Prognose

Koersdoel

By TipRanks

190.6% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 28.13 USD 190.6%

Hoogste 40 USD

Laagste 15 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kura Oncology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Kura Oncology Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.575 / 6.6Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

41 / 346 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.